[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614606":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":33,"responsibleParty":52,"collaborators":19,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":19,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":19,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":36,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nelfinavir","EXPERIMENTAL","Given Orally",[13],"Drug: Nelfinavir",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Taken twice daily",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Angela Flesichman, MD, PhD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":32,"role":28,"phone":19,"phoneExt":19,"email":19},"University of California Irvine Medical",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Chao Family Comprehensive Cancer Center, University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.85311,33.78779,{"lat":46,"lon":45},[49],{"name":50,"role":28,"phone":51,"phoneExt":19,"email":30},"Angela Fleischman, MD, PhD","877-827-8839",{"type":24,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Angela G. Fleischman","Associate Professor","100614606","phase-1-treating-anemia-in-myelofibrosis-with-repurposed-drugs-nelfinavir-that-restore-iron-delivery-to-the-bone-marrow-100614606",false,"NCT07281781","Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow","Inclusion Criteria:\n\n* ≥18 years of age\n* Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria\n* Has a hemoglobin ≤ 10gm\u002FdL at screening\n* Serum ferritin ≥ 100\n* May continue on current MPN treatment, including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide.\n* Peripheral blast count \\\u003C10% during Screening.\n* Free of other known active or metastatic malignancies other than localized skin cancer.\n* Amenable to blood draws and symptom assessments.\n* Agree to the use of contraceptives. Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential, should both use an effective contraception method during the study and continue to use contraception for 60 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3\n* Currently pregnant or planning on being pregnant within the study period.\n* Currently taking Momelotinib or Pacritinib (these agents are purported to reduce hepcidin).\n* Currently taking any of the contraindicated medications to Nelfinavir listed in section 13.2\n* Currently breastfeeding.\n* Known uncontrolled active viral or bacterial infection.\n* Known HIV+\n* Significant impairment of major organ or hematopoietic function defined as\n\n  1. Serum creatinine clearance less than 30 ml\u002Fmin (eGFR).\n  2. Bilirubin more than 1.5 mg\u002Fdl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.\n  3. Platelets \\\u003C 50 × 10\\^9\u002FL without transfusions\n  4. ANC \\\u003C 0.75 × 10\\^9\u002FL without growth factors\n* Known history of allergic reaction to nelfinavir.","ALL","18 Years",{"count":64,"type":65},10,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE1","PHASE2","This is a phase I\u002FII protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.",[72,73],"Myelofibrosis","Myelofibrosis; Anemia",[72,75,9],"Anemia","2026-04-28",{"date":78,"type":79},"2026-05-04","ACTUAL",{"date":81,"type":79},"2025-09-16",{"date":83,"type":65},"2027-06",{"name":5,"class":6},1]